Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Black squares indicate samples with national coverage; blue triangles indicate samples with subnational (including local or regional) coverage.
Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.
Data for Denmark, Germany, Italy and part of the data from Lithuania and Portugal include non-IDUs and therefore may underestimate prevalence among IDUs (estimated proportion of non-IDUs in the samples: Denmark 45 %. Lithuania, Italy, Germany and Portugal not known).
Data for Italy, Cyprus, Luxembourg, Malta, The Netherlands, Portugal, Romania and Slovakia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. In addition, data may not be representative for people who are in treatment — this is known to be the case for Belgium. Part of data for Cyprus and Luxembourg, are based on self-reported test results, which are less reliable than clinically documented tests.
Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.
Statistical bulletin 2010: Figure INF-3 parti
For primary sources, study details and data before 2008, see Table INF-108 and Table INF-0.
See also ‘General notes for interpreting data’ on the Explanatory notes and help page
(see the help page for information about formats etc.)
Page last updated: Tuesday, 02 August 2011